title: Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function.
abstract: OBJECTIVE
  To study the combined potential of wild-type p53 gene transfer and administration of cisplatin for the treatment of glioblastoma multiforme, the authors used the 9L rat glioblastoma cell line, which expresses a mutant p53.
  
  
  METHODS
  Stable expression of wild-type p53 in 9L cells was achieved by transfection of the cells with a wild-type p53-expressing plasmid (pCEP4p53). The resultant cell line, 9LpCEP4p53, was found to be more sensitive to cisplatin treatment in vitro than control (9LpCEP4) cells. The in vitro growth rates of control cells and wild-type p53-modified cells were similar in the absence of cisplatin. Fischer 344 rats were implanted intracerebrally with 9LpCEP4p53 cells and intraperitoneally administered 4 mg/kg cisplatin weekly for 7 weeks. These animals survived significantly longer than animals that were implanted with 9LpCEP4p53 cells but were given no cisplatin treatment. In contrast, concurrent cisplatin treatment provided no benefit for animals implanted with 9LpCEP4 cells. Tumors that developed in animals that had been implanted with 9LpCEP4p53 cells and treated with cisplatin had lost expression of wild-type p53, indicating a correlation between expression of wild-type p53 and cisplatin sensitivity in vivo.
  
  
  CONCLUSIONS
  The findings of this study suggest that p53-based gene therapy in combination with cisplatin-based chemotherapy may be superior to single-modality treatment in dealing with glioblastoma multiforme.
authors.affiliation: Sidney Kimmel Cancer Center, San Diego, California 92121, USA.
authors.forename: O
authors.initials: O
authors.lastname: Dorigo
authors.forename: S T
authors.initials: ST
authors.lastname: Turla
authors.forename: S
authors.initials: S
authors.lastname: Lebedeva
authors.forename: R A
authors.initials: RA
authors.lastname: Gjerset
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy / Q000235:genetics; D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics; D018014:Gene Transfer Techniques; D016158:Genes, p53 / Q000235:genetics*; D015316:Genetic Therapy; D005909:Glioblastoma / Q000188:drug therapy / Q000235:genetics*; D004854:Herpesvirus 4, Human / Q000235:genetics; D007274:Injections, Intraperitoneal; D009154:Mutation / Q000235:genetics*; D009368:Neoplasm Transplantation; D010957:Plasmids; D051381:Rats; D011916:Rats, Inbred F344; D012044:Regression Analysis; D015996:Survival Rate; D014162:Transfection; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin